Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Trading 01-10 14:16:52 EST

1.26

-0.07

-5.64%

High1.33	Low1.25	Vol328.68K
Open1.32	D1 Closing1.33	Amplitude6.24%
Mkt Cap20.78M	Tradable Cap13.26M	Total Shares16.56M
T/O417.79K	T/O Rate3.11%	Tradable Shares10.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.255,"timestamp":1736536567837,"preClose":1.33,"halted":0,"volume":328676,"delay":0,"floatShares":10569382,"shares":16560852,"eps":-0.572298,"marketStatus":"Trading","change":-0.075,"latestTime":"01-10 14:16:52 EST","open":1.32,"high":1.333,"low":1.25,"amount":417793.0134344,"amplitude":0.062406,"askPrice":1.26,"askSize":600,"bidPrice":1.25,"bidSize":418,"shortable":0,"etf":0,"ttmEps":-0.572298,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1736542800000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.33,"preHourTrading":{"tag":"盘前","latestPrice":1.3595,"preClose":1.33,"latestTime":"08:59 EST","volume":3326,"amount":4467.0062516,"timestamp":1736517554541},"postHourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.33,"latestTime":"19:57 EST","volume":13433,"amount":17835.4305,"timestamp":1736384249187},"volumeRatio":0.664717},"requestUrl":"/m/hq/s/MIRA/wiki","defaultTab":"wiki","newsList":[{"id":"2501144214","title":"Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2501144214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501144214?lang=en_us&edition=fundamental","pubTime":"2025-01-05 21:16","pubTimestamp":1736083001,"startTime":"0","endTime":"0","summary":"So, the natural question for MIRA Pharmaceuticals  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since its cash burn is increasing , MIRA Pharmaceuticals shareholders should still be mindful of the possibility it will require more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-131641039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4588","LU2095319765.USD","IE00BKPKM429.USD","BK4007","LU2210149790.SGD","TQQQ","MIRA","QID","TSYW.SI","USAW.SI","NVIW.SI","SQQQ","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","QLD","NQmain","BK4112","MNQmain","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","PSQ",".IXIC"],"gpt_icon":1},{"id":"2495911006","title":"MIRA Dad Siqi Chen Faces Rug Pull Allegations Over ‘Zero’ Token","url":"https://stock-news.laohu8.com/highlight/detail?id=2495911006","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495911006?lang=en_us&edition=fundamental","pubTime":"2024-12-31 19:30","pubTimestamp":1735644600,"startTime":"0","endTime":"0","summary":"Siqi Chen faces accusations of a rug pull with his 'Zero' token.Despite clarifying intentions and burning profits, Chen faced backlash for repeated missteps.Chen has promised to reimburse affected wallets personally.After raising funds for cancer research through crypto following his daughter’s diagnosis, Runway CEO Siqi Chen appears to have found himself in troubled waters.Siqi Chen has now been accused of a rug pull using the token ‘zero.’。When his daughter Mira Chen was diagnosed with a brain tumor, Siqi Chen took to social media asking supporters to donate to a children’s brain tumor fund. An X user then created a meme coin on Solana called MIRA to support the research efforts. Half the supply of the MIRA tokens was sent to Chen.However, because Siqi Chen used the same donation wallet address in the past few days to issue this new meme coin, many investors bought in. Thus, pushing the token’s market cap past $6 million in just an hour.However, blockchain sleuth ZachXBT pointed out ","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2024/11/scam-hack-hackers-bic-es-850x478.jpeg.optimal.jpeg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2024/11/scam-hack-hackers-bic-es-850x478.jpeg.optimal.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/siqi-chen-faces-rug-pull-allegations/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2495664486","title":"MIRA dad vows to repay losses from rugged test token ZERO","url":"https://stock-news.laohu8.com/highlight/detail?id=2495664486","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495664486?lang=en_us&edition=fundamental","pubTime":"2024-12-31 17:49","pubTimestamp":1735638563,"startTime":"0","endTime":"0","summary":"Siqi Chen, the father that inspired the MIRA token, has apologized to the crypto community for creating a test token called ZERO and selling 40% of its supply. He vows to repay the losses suffered by affected wallets.In a recent X post, Chen told his followers that he had launched what he referred to as a “test token” called ZERO on the Solana  meme coin launch platform, pump.fun.The description of the token warns traders that its value will fall to zero and it is guaranteed that anyone who buys ZERO will lose all the money they invest in it. The description even outright tells traders not to buy it because “it does nothing and never will. It is worth zero.”In a separate post, he apologized on behalf of the MIRA and Solana communities and vows to restore “every single wallet that has lost money as a result of my actions.”Formally, Siqi Chen is known as the co-founder and CEO of a company called Runway. Though, to the crypto community he is known as the father of a four-year old g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6773be24a22aea512dd4ab98/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["MIRA","SOL","BK4129","BK4519","BK4007"],"gpt_icon":0},{"id":"2494046388","title":"Whale loses $500K on MIRA token as charity token trend gains ground","url":"https://stock-news.laohu8.com/highlight/detail?id=2494046388","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494046388?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:54","pubTimestamp":1735307687,"startTime":"0","endTime":"0","summary":"A whale lost $500K on the MIRA token, which built up hype around being linked to rare disease research. The token was tied to Siqi Chen, co-founder of Serious Business and Runway, with no previous connections to crypto or memes.The MIRA token saw active trading after a big part of the supply was sent to Siqi Chen, co-founder of Serious Business and Runway. The initial hype around the token suggested the asset would be used to fund research into rare diseases. However, soon after the launch, MIRA went through extreme volatility.Recently, MIRA wiped as much as $500K from a whale trader, who poured more than $1.56M into the token. The buyer is still holding, though. Within hours, the value of the token holdings fell to $718,000, extending its downward trend. Despite the noble cause, once Chen sold his share and whales took profit, the token did not find support from anywhere else.Before whales realized profits, Chen held up to $18M worth of MIRA tokens. Initially, the share was worth $400","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676eb1a88a03c8196e11c888/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2494877454","title":"Crypto Whale Turns $81.3K into $13.36M Profit with MIRA and FARTCOIN Tokens: A 1030x Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2494877454","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494877454?lang=en_us&edition=fundamental","pubTime":"2024-12-27 17:31","pubTimestamp":1735291872,"startTime":"0","endTime":"0","summary":"A crypto whale has received widespread attention after earning a huge profit by accumulating massive amounts of Chains of War (MIRA) and Fartcoin (FARTCOIN) tokens. The whale swapped $69,100 for MIRA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676e73df3b1253069be45e7a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["APT.USD.CC","TON.USD.HKCC","TON.USD.CC","RNDR.USD.HKCC","BK4007","APT.USD.HKCC","MIRA"],"gpt_icon":0},{"id":"2492717661","title":"MIRA Pharmaceuticals submits IND to FDA for Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2492717661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492717661?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:15","pubTimestamp":1734617715,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA), has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Ketamir-2, its nove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-submits-ind-to-fda-for-ketamir-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-submits-ind-to-fda-for-ketamir-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2492517061","title":"MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492517061","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492517061?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein , which allows for better oral absorption and enhanced blood-brain barrier ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-submits-ind-ketamir-140000120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","CAGR","ABVC","BK4007","BK4139","BK4159"],"gpt_icon":0},{"id":"2492134178","title":"Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2492134178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492134178?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:34","pubTimestamp":1734615257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK0FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2492075921","title":"EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2492075921","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492075921?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:25","pubTimestamp":1734614707,"startTime":"0","endTime":"0","summary":"On Thursday, MIRA Pharmaceuticals, Inc.  said it submitted an Investigational New Drug  application to the FDA to start human trials for Ketamir-2, its novel oral ketamine analog for neuropathic pain.An IND is submitted to propose studying an unapproved drug or an approved product for a new indication or in a new patient population.The company’s IND application includes comprehensive data and reports detailing Ketamir-2’s pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models.In parallel with the submission, the company is conducting a neurotoxicity study, as required by the FDA’s written feedback, to support the initiation of human dosing in the U.S.Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain. MIRA is also advancing MIRA-55, with preclinical trials targeting memory, cognition, and anxiety, and plans to ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XlKpU41fb7dZ50sdK1frtQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/660745cf8b3ba74acd71ae58169044f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XlKpU41fb7dZ50sdK1frtQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/660745cf8b3ba74acd71ae58169044f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-files-fda-132507382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2492170619","title":"MIRA Makes Major Strides","url":"https://stock-news.laohu8.com/highlight/detail?id=2492170619","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492170619?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:05","pubTimestamp":1734602700,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.We remain extremely positive on MIRA, and this announcement is yet further confirmation that the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-makes-major-strides-100500635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2490158340","title":"Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490158340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490158340?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2490015866","title":"Mira Pharmaceuticals Inc: Validates Ketamir-2'S Safety Profile With No Adverse Findings, Paving Way for Ind Submission by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015866?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2490015860","title":"Mira Pharmaceuticals Inc: Plans to Initiate Phase I Clinical Trials for Ketamir-2 in Q1 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490015860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490015860?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:47","pubTimestamp":1733838431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nFWN3NB02J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2490531016","title":"MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2490531016","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490531016?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:30","pubTimestamp":1733837400,"startTime":"0","endTime":"0","summary":"Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain. MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, proudly announces the successful completion of its current Good Laboratory Practice  preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm no adverse findings, clearing a critical milestone as the Company progresses toward submitting its Investigational New Drug  application by year-end 2024.\"Our commitment to advancing Ketamir-2 into clinical trials as quickly as possible reflects our strategic focus on generating proof-of-concept data that positions MIRA for a potential M&A transaction or strategic partnership,\" said Erez Aminov, CEO and Chairman of MIRA. \"This milestone demonstrates our ability to execute efficiently and reinforces our dedication to delivering innovative, safe, and effective treatments for patients suffering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-validates-ketamir-2s-133000864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","GLP","BK4144","BK4590","BK4007"],"gpt_icon":0},{"id":"2490013384","title":"EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013384","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013384?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:15","pubTimestamp":1733836517,"startTime":"0","endTime":"0","summary":"On Tuesday, MIRA Pharmaceuticals, Inc.  said it completed the current Good Laboratory Practice preclinical safety program for Ketamir-2, a novel oral ketamine analog.The results confirm no adverse findings, clearing a critical milestone as the company progresses toward submitting its Investigational New Drug  application by year-end 2024.Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain. The company says that by demonstrating Ketamir-2’s robust safety profile in comprehensive preclinical studies, MIRAhas significantly de-risked this critical aspect of drug development.This milestone positions the company for a smoother regulatory pathway, potentially increasing the likelihood of successful clinical outcomes.Cardiovascular Safety in Dogs: No adverse effects were noted at therapeutic doses.Building on the Phase 1 findings, MIRA plans to initiate a Phase 2a proof-of-concept study in Q4 2025, focusing on patients wi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PTh5gnwlEiCInrLg5qLVtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/fd337e3099329830e61f441b2093ca6d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PTh5gnwlEiCInrLg5qLVtA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/fd337e3099329830e61f441b2093ca6d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-validates-ketamir-131517884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2485426470","title":"MIRA Pharmaceuticals Appoints New Board Member and Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426470?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:48","pubTimestamp":1732225696,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an update. MIRA Pharmaceuticals, Inc. announces a significant leadership change as Michael Jerman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-board-member-and-chairman?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2484011565","title":"MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2484011565","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484011565?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:44","pubTimestamp":1732106640,"startTime":"0","endTime":"0","summary":"Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment. MIAMI, FL / ACCESSWIRE / November 20, 2024 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research  in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025. The Phase IIa study, planned to start in Q4 2025, will focus on diabetic neuropathy patients, with initial human efficacy results anticipated in the first half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-reveals-innovative-phase-iia-124400230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2483832346","title":"MIRA Continues Solid Financial Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2483832346","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483832346?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just released further study results that, in our view, boost the potential for the treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-continues-solid-financial-management-110000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2479282498","title":"MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2479282498","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479282498?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:57","pubTimestamp":1730213864,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  shares soared by 40% after the company achieved a significant breakthrough in chemotherapy pain management with its new drug, Ketamir-2. According to recent studies, Ketamir-2 is proven to be 2% more effective than existing FDA-approved medications, specifically Gabapentin and Pregabalin, in alleviating chemotherapy-induced neuropathic pain. Preclinical studies have highlighted Ketamir-2's superior performance, demonstrating a 60% higher efficacy compared to Gabapentin and a remarkable 112% improvement over Pregabalin in various neuropathic models.GuruFocus has detected 4 Warning Signs with TMDX.In addition to ketamine-2, MIRA Pharmaceuticals is also active in developing MIRA-55, an oral agent with a similar mechanism as ketamine-2 used in the treatment of anxiety and cognitive symptoms in early dementia. With Ketamir-2 moving towards clinical trial and possibly receiving expedited approval by the FDA, it becomes a true light at the end of the tunnel for those suf","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BWrQl6JsGtld4ws6on8CBg--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/6b4169c961bedd8366201c4b184072f0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BWrQl6JsGtld4ws6on8CBg--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/6b4169c961bedd8366201c4b184072f0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-shares-surge-40-145744961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2479437743","title":"MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479437743","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479437743?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:40","pubTimestamp":1730137258,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc.  stock is trading higher on Monday after the company released new preclinical findings from Ketamir-2, a novel oral ketamine analog.The new preclinical data show that Ketamir-2 is 60% more effective than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain.Also Read: MIRA Pharmaceuticals’ Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies. On Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provided only moderate relief.To maximize the development timeline, MIRA is considering conducting multiple Phase 2 trials in parallel, specifically targeting neuropathic pain across different patient populations, which could further accelerate Ketamir-2’s path to market.In addition to the ongoing studies, MIRA is in the process of submitting several scientific journal publications that","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/92kmnbogljGXGlbq7JI58A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/504361aa1cf5cd6d696519cc9da86e9f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-formulated-shows-greater-174058339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VFF","MIRA","BK4007","BK4189","SAVAW","SAVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.1667},{"period":"1month","weight":0.0813},{"period":"3month","weight":0.2315},{"period":"6month","weight":1.2573},{"period":"1year","weight":0.2315},{"period":"ytd","weight":0.1667}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction